Bladder cancer trial pits radiotherapy against standard immunotherapy
NCT ID NCT07268339
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial compares radiotherapy with a radiosensitiser to the standard BCG immunotherapy for high-risk non-muscle invasive bladder cancer. About 328 patients will be randomly assigned to one of the two treatments after tumor removal. The goal is to see which approach better prevents cancer from coming back or getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiotherapy with radiosensitisation (gemcitabine, mitomycin C/fluorouracil, or carbogen/nicotinamide)
What this could lead to
If successful, this could offer a more effective alternative to BCG for high-risk bladder cancer, reducing recurrence and the need for bladder removal.
What could go wrong
This is an early-stage trial with 328 participants, and radiotherapy may cause side effects like bladder or bowel irritation. It may not prove superior to BCG.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Christie
Manchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••